In our sampling, the well-established NSCLC biomarkers such as TMB and expression level of PD-L1 (CD274) gene showed insufficient capacity of distinguishing patients by PFS and/or by RECIST treatment response (Supplementary Table 3). This evidence concerns the gene CD274 and non-small cell lung carcinoma.